DMart Stock: Avenue Supermarts Builds Out Pharmacy Business

What DMart's Pharmacy Push Changed

Avenue Supermarts, which runs the DMart chain, has been building out a pharmacy business inside its stores, offering medicines at a 20% discount. The move has so far happened with little fanfare compared to DMart's usual grocery and household goods push, but it adds a new category to a retailer that built its reputation on low prices and high shelf turnover.

Why DMart Stock Is in Focus

DMart's model rests on driving footfall through everyday low prices on staples, then using scale to keep margins intact even on thin pricing. Pharmacy is a natural extension of that playbook: medicines are a recurring, non discretionary purchase, and a discount pharmacy counter inside an existing store adds a reason for shoppers to visit more often without the company needing to open new locations. It also puts DMart in more direct contact with a category that quick commerce apps have been racing to capture through fast medicine delivery.

Which Stocks, and Why

The effect is direct and confined to Avenue Supermarts. A discounted, in-store pharmacy can lift basket sizes and visit frequency at existing outlets, which matters for a company that grows earnings mainly through better sales per store rather than through opening many new stores each year. Because medicines carry different margins and regulatory requirements than groceries, how well DMart executes this, sourcing, staffing pharmacists and managing compliance, will determine how much this adds to the bottom line rather than just gross revenue.

What to Watch

Investors should watch how many stores roll out the pharmacy counter and over what timeframe, since a pilot in a handful of locations is a very different signal from a chain wide rollout. Commentary in DMart's upcoming quarterly results about new categories and same-store sales growth should show whether the pharmacy push is starting to show up in the numbers.